ERLOCIP 150MG TABLET contains Erlotinib which belongs to the group of medicines called Kinase inhibitors. It is used in adults to manage non-small cell lung cancer at an advanced stage, as initial therapy (or as therapy if disease remains largely unchanged after initial chemotherapy, provided your cancer cells have specific EGFR mutations).
It is also used if previous chemotherapy has not helped to stop the disease and to manage cancer of the pancreas at a metastatic stage in combination with gemcitabine. Cancer can be defined as body cells beginning to grow out of control. Cells in any part of the body can become cancer cells and can spread to other areas of the body. Your doctor may perform certain blood tests prior to the management.
Avoid smoking during the management of ERLOCIP 150MG TABLET, as it decreases the effect of the medicine. ERLOCIP 150MG TABLET is not recommended for use if you have severe liver or kidney disease. Before taking ERLOCIP 150MG TABLET inform your doctor if you have diarrhea, glucuronidation disorder like Gilbert’s syndrome, history of peptic ulcers or diverticular disease, you use contact lenses, or have a history of eye problems (severe dry eyes, inflammation or ulcers of the cornea).
ERLOCIP 150MG TABLET is generally not recommended for use in pregnant and breastfeeding women unless considered clearly necessary, therefore consult your doctor before taking it. ERLOCIP 150MG TABLET is not recommended for use in children and adolescents below 18 years of age. The most common side effects of taking ERLOCIP 150MG TABLET are rash, infection, loss of appetite, decreased weight, or depression. Contact your doctor if any of the symptoms worsen.
No content available
